Substance P and Fibromyalgia

REFERENCES

• Wolfe F, Smythe H A, Yunus M B, Bennett R M, Bombardier C, Goldenberg D L, Tugwell P, Campbell S M, Abeles M, Clark P, Fam A G, Farber S J, Fiechtner J J, Franklin C M, Gatter R A, Hamaty D, Lessard J, Lichtbroun A S, Masi A T, McCain G A, Reynolds W J, Romano T J, Russell I J, Sheon R P. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Arthritis Rheum 1990; 33: 160–172
   PubMed Web of Science ®Google Scholar
• Bonica J J. Definitions and Taxonomy of Pain. The Management of Pain, 2nd Edition, J J Bonica, J D Loeser, C R Chapman, W E Fordyce. Lea & Febiger, Philadelphia 1990; Volume I: 18–27
   Google Scholar
• Hoheisel U, Mense S, Ratkai M. Effects of spinal cord supervision with substance P on the excitability of rat dorsal horn neurons processing input from deep tissues. J Musculoske Pain 1996; 3(3)23–43
   Google Scholar
• Malmberg A B, Yaksh T L. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science 1992; 257: 1276–1279
   PubMed Web of Science ®Google Scholar
• Vaeroy H, Helle R, Forre O, Kass E, Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud's phenomenon in patients with fibromyalgia: New features for diagnosis. Pain 1988; 32: 21–26
   PubMed Web of Science ®Google Scholar
• Russell I J, Orr M D, Littman B, Vipraio G A, Alboukrek D, Michalek J E, Lopez Y, MacKillip F. Elevated cerebrospinal levels of substance P patients fibromyalgia syndrome. Arthritis Rheum 1994; 37: 1593–1601
   PubMed Web of Science ®Google Scholar
• Welin M, Bragee B, Nyberg F, Kristiansson M. Elevated substance P levels are contrasted by a decrease in met-enkephalin-arg-phe levels in csf from fibromyalgia patients. J Musculoske Pain 1995; 3(Suppl #1), 4, (Abstract)
   Google Scholar
• Alberts K R, Bradley L A, Mountz J M, Blalock J E, Jiu J G, Weigent D A, Triana-Alexander M, Alexander R W, Aaron L A, Martin M Y, Morell A C, Alarcon G S. Regional cerebral blood flow (rCBF) in the caudate nucleus and thalamus of fibromyalgia (FM) patients is associated with the cerebrospinal fluid (CSF) levels of substance P (SP). 8th World Congress on Pain, Aug 17–22. IASP Press, Seattle, WA 1996; 445, (Abstract)
   Google Scholar
• Paik M. A graphic representation of a three-way contingency table: Simpson's paradox and correlation. American Statistician 1985; 39: 53–54
   Web of Science ®Google Scholar
• Mejia J A, Pernow J, von Holst H, Rudehill A, Lundberg J M. Effects of neuropeptide Y, calcitonin gene-related peptide, substance P, and capsaicin on cerebral arteries in man and animals. J Neurosurg 1988; 69: 913–918
   PubMedGoogle Scholar
• Nyberg F, LeGreves P, Sundqvist C, Terenius L. Characterization of substance P (1–7) and (1–8) generating enzyme in human cerebrospinal fluid. Biochem Biophys Res Commun 1984; 125: 244–250
   PubMed Web of Science ®Google Scholar
• Skilling S R, Smullin D H, Larson A A. Differential effects of C- and N-terminal substance P metabolites on the release of amino acid neurotransmitters from the spinal cord: potential role in nociception. Journal of Neuroscience 1990; 10: 1309–1318
   PubMed Web of Science ®Google Scholar
• Yukhananov RYu, Larson A A. An N-terminal fragment of substance P, Substance P (1–7), down-regulates neurokinin-1 binding in the mouse spinal cord. Neuroscience 1994; 178: 163–166
   Google Scholar
• Hornfeldt C S, Sun X, Larson A A. The NH2-terminus of substance P modulates NMDA-induced activity in the mouse spinal cord. J Neurosci 1994; 14: 3364–3369
   PubMedGoogle Scholar
• Sharma H S, Nyberg F, Olsson Y, Dey P K. Alteration of substance P after trauma to the spinal cord: An experimental study in the rat. Neuroscience 1990; 38: 205–212
   PubMed Web of Science ®Google Scholar
• Giovengo S L, Russell I J, Larson A A. Elevated concentrations of nerve growth factor (NGF) in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol 1998, (in press)
   Google Scholar
• Donnerer J, Schuligoi R, Stein C. Increased content and transport of substance P and calcitonin gene-related peptide in sensory nerves innervating inflammed tissue: Evidence for a regulatory function of nerve growth factor in vivo. Neuroscience 1992; 49: 693–698
   PubMed Web of Science ®Google Scholar
• Often U, Goedert M, Mayer M, Lembeck F. Requirement of nerve growth factor for the development of substance P containing neurones. Nature 1980; 287: 158–159
   PubMedGoogle Scholar
• Woolf C J, Shortland P, Coggeshall R E. Peripheral nerve injury triggers central sprouting of myelinated afferents. Nature 1992; 355: 75–78
   PubMed Web of Science ®Google Scholar
• Andreev N Y, Dimitrieva A N, Koltzenburg M, McMohon S B. Peripheral administration of nerve growth factor in the adult rat produces a thermal hyperalgesia that requires the presence of sympathetic post-ganglionic neurones. Pain 1995; 63: 109–116
   PubMed Web of Science ®Google Scholar
• Tamatani M, Senba E, Tohyama M. Calcitonin gene-related peptide- and substance P-containing primary afferent fibers in the dorsal column of the rat. Brain Res 1989; 495: 122–130
   PubMedGoogle Scholar
• McNeill D L, Westlund K N, Coggeshall R E. Peptide immunoreactivity of unmyelinated primary afferent axons in rat lumbar dorsal roots. J Histochem Cytochem 1989; 37: 1047–1052
   PubMedGoogle Scholar
• NcNeill D L, Chung K, Carlton S M, Coggeshall R E. Calcitonin gene-related peptide immunostained axons provide evidence for fine primary afferent fibers in the dorsal and dorsolateral funiculi of the rat spinal cord. J Comp Neurol 1988; 272, 303–308
   Google Scholar
• Eide P K, Hole K. Interactions between serotonin and substance P in the spinal regulation of nociception. Brain Res 1991; 550: 225–230
   PubMedGoogle Scholar
• Walker P D, Riley L A, Hart R P, Jonakait G M. Serotonin regulation of tachykinin biosynthesis in the rat neostriatum. Brain Res 1991; 546: 33–39
   PubMedGoogle Scholar
• Murphy R M, Zemlan F P. Differential effects of substance P on serotonin-modulated spinal nociceptive reflexes. Psychopharmacology (Berlin) 1987; 93: 118–121
   PubMed Web of Science ®Google Scholar
• Russell I J, Michalek J E, Vipraio G A, Fletcher E M, Javors M A, Bowden C A. Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. J Rheumatol 1992; 19: 104–109
   PubMed Web of Science ®Google Scholar
• Russell I J, Vipraio G A. Serotonin (5HT) in serum and platelets (PLT) from fibromyalgia patients (FS) and normal controls (NC). Arthritis Rheum 1994; 37(Suppl)S214
   Google Scholar
• Nyberg F, Liu Z, Lind C, Thornwall M, Ordeberg G. Enhanced CSF levels of substance P in patients with painful arthrosis but not in patients with pain from herniated lumbar discs. J Musculoske Pain 1995; 3(Suppl #1), 2, (Abstract)
   Google Scholar
• Towle A C, Mueller R A, Breese G R, Lauder J. Altered respiratory response to substance P in capsaicin-treated rats. J Neurosci Res 1985; 14: 239–253
   PubMedGoogle Scholar
• Almay B G, Johansson F, von Knorring L, Le Greves P, Terenius L. Substance P in CSF of patients with chronic pain syndromes. Pain 1988; 33: 3–9
   PubMed Web of Science ®Google Scholar
• Cramer H, Rosier N, Rissler K, Gagniew M C, Renaud B. Cerebrospinal fluid immunoreactive substance P and somatostatin in neurological patients with peripheral and spinal cord disease. Neuropeptides 1988; 12: 119–124
   PubMedGoogle Scholar